Drug Profile


Alternative Names: AMR 69; Deskar; Esbriet; Etuary; F 647; Pirespa; RO 0220912; S 7701

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator KDL Gmbh; Marnac
  • Developer AFT Pharmaceuticals; Beijing Continent Pharmaceutical; Il Dong; Roche; Shanghai Genomics; Shionogi
  • Class Anti-inflammatories; Antifibrotics; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Interstitial lung diseases
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic pulmonary fibrosis
  • Phase II Acute lung injury; Heart failure
  • Preclinical Diabetic nephropathies; Interstitial lung diseases
  • Discontinued Glomerulonephritis; Multiple sclerosis; Peritoneal fibrosis; Renal fibrosis; Retinal disorders; Scleroderma

Most Recent Events

  • 30 Jan 2017 Phase-II clinical trials in Heart failure (In adults, In the elderly) in United Kingdom (PO) (ISRCTN91621241)
  • 07 Nov 2016 Launched for Idiopathic pulmonary fibrosis in Taiwan (PO)
  • 20 Oct 2016 Phase-II clinical trials in Idiopathic pulmonary fibrosis (Combination therapy) in Belgium, Hungary (PO) (NCT02951429) (EudraCT2015-005131-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top